Doximity, Inc. (DOCS) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts are broadly neutral on Doximity: Twenty-five firms have an average “Hold” rating, with a 12-month price target of $31.95. Ratings include 14 holds, seven buys, one strong buy and three sells.
• Doximity exceeded quarterly EPS expectations, reporting $0.29 versus the $0.16 consensus, while revenue rose 7.3% year over year to $156.62 million. The stock recently traded at $30.38, above its 50-day and 200-day moving averages.
• Risks remain significant: A securities class action alleges market-share losses, reduced fiscal 2026 guidance and a revenue shortfall, while insiders have sold $533,688 of stock over the past three months. RBC Capital reaffirmed its Buy rating, providing some offsetting positive sentiment.

Shares of Doximity, Inc. (NYSE:DOCS - Get Free Report) have been assigned an average recommendation of "Hold" from the twenty-five ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $31.95.

A number of analysts have commented on DOCS shares. Zacks Research raised shares of Doximity from a "strong sell" rating to a "hold" rating in a report on Monday, July 13th. Wells Fargo & Company cut shares of Doximity from an "equal weight" rating to an "underweight" rating and set a $18.00 price target on the stock. in a research note on Monday, August 10th. Weiss Ratings raised shares of Doximity from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, October 6th. Canaccord Genuity Group set a $36.00 price objective on Doximity in a research note on Friday, August 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $41.00 target price on shares of Doximity in a report on Friday, August 7th.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: RBC Capital reaffirmed its Buy rating on Doximity, providing continued sell-side support for the stock. RBC Capital Reaffirms Their Buy Rating on Doximity
• Positive Sentiment: A valuation analysis considers whether Doximity is below fair value following the recent AI spending surge, potentially reinforcing the view that the shares offer upside if the company can benefit from artificial intelligence investment. Is Doximity Below Fair Value Following the AI Spending Surge?
• Neutral Sentiment: A review of vertical software companies’ second-quarter results puts Doximity’s recent performance in the broader sector context, but does not introduce a new company-specific catalyst. Reflecting on Vertical Software Stocks’ Q2 Earnings: Doximity
• Negative Sentiment: Several law firms, including Rosen, Kaplan Fox, SBS, Bronstein Gewirtz & Grossman, SueWallSt, Pomerantz and Robbins Geller, are publicizing a securities class action against Doximity. The allegations concern claimed loss of market share, reduced fiscal 2026 revenue guidance and a subsequent revenue shortfall. Investors have until November 16, 2026 to seek a lead-plaintiff role, increasing legal and reputational risk for DOCS. Rosen Doximity Securities Class Action Notice

Insider Buying and Selling

In other Doximity news, CAO Siddharth Sitaram sold 2,077 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $26.02, for a total transaction of $54,043.54. Following the completion of the sale, the chief accounting officer owned 96,045 shares of the company's stock, valued at approximately $2,499,090.90. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Phoebe Yang sold 1,290 shares of the company's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $26.71, for a total value of $34,455.90. Following the completion of the sale, the director owned 24,744 shares of the company's stock, valued at approximately $660,912.24. The trade was a 4.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 16,637 shares of company stock valued at $533,688 over the last three months. 31.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its holdings in Doximity by 19.8% during the third quarter. GAMMA Investing LLC now owns 5,834 shares of the company's stock valued at $165,000 after purchasing an additional 963 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Doximity by 265.4% in the third quarter. Farther Finance Advisors LLC now owns 7,180 shares of the company's stock worth $203,000 after purchasing an additional 5,215 shares in the last quarter. Apella Capital LLC increased its stake in shares of Doximity by 1.4% in the third quarter. Apella Capital LLC now owns 59,488 shares of the company's stock worth $1,647,000 after purchasing an additional 802 shares in the last quarter. Versant Capital Management Inc increased its stake in shares of Doximity by 1,176.9% in the third quarter. Versant Capital Management Inc now owns 1,826 shares of the company's stock worth $52,000 after purchasing an additional 1,683 shares in the last quarter. Finally, Tidal Investments LLC raised its position in shares of Doximity by 207.9% during the 2nd quarter. Tidal Investments LLC now owns 43,761 shares of the company's stock valued at $908,000 after purchasing an additional 29,546 shares during the period. 87.19% of the stock is owned by hedge funds and other institutional investors.

Doximity Price Performance

NYSE DOCS opened at $30.38 on Monday. The business's fifty day moving average price is $25.95 and its 200-day moving average price is $23.40. Doximity has a 1-year low of $17.15 and a 1-year high of $72.24. The stock has a market capitalization of $5.42 billion, a price-to-earnings ratio of 35.74, a PEG ratio of 23.86 and a beta of 1.22.

Doximity (NYSE:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.13. The company had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business's quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.36 EPS. Equities research analysts anticipate that Doximity will post 0.74 EPS for the current year.

About Doximity

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.